-
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial
Toorop, A. A., Wessels, M. H. J., Gelissen, L. M. Y., Hoitsma, E., Zeinstra, E. M. P. E., van Rooij, L. C., van Munster, C. E. P., Vennegoor, A., Mostert, J. P., Wokke, B. H. A., Kalkers, N. F., Hoogervorst, E. L. J., van Eijk, J. J. J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L. G. F., Kloosterziel, M. E., & 11 others, 15 Jul 2024, In: Journal of the neurological sciences. 462, p. 123102 123102.Research output: Contribution to journal › Article › Academic › peer-review
-
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Toorop, A. A., van Lierop, Z. Y., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., van Eijk, J. J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L., Kloosterziel, M. E., & 16 others, 14 Nov 2023, (E-pub ahead of print) In: Journal of neurology, neurosurgery, and psychiatry.Research output: Contribution to journal › Article › Academic
-
High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate
Doesburg, D., Vennegoor, A., Uitdehaag, B. M. J. & van Oosten, B. W., 1 Jun 2019, In: Multiple Sclerosis and Related Disorders. 31, p. 32-37 6 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
